Download PDF
Semin Neurol 2020; 40(01): 083-086
DOI: 10.1055/s-0039-3402067
Review Article
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Vestibular Migraine: Treatment and Prognosis

Michael von Brevern
1   Neurologisches Zentrum, Berlin, Germany
,
Thomas Lempert
2   Department of Neurology, Schlosspark-Klinik, Berlin, Germany
› Author Affiliations
Further Information

Publication History

Publication Date:
30 December 2019 (online)

    Permissions and Reprints

Abstract

Treatment of vestibular migraine currently lacks a firm scientific basis, as high quality randomized controlled trials are not available. Therefore, recommendations are largely borrowed from the migraine sphere. The first therapeutic step is explanation and reassurance. Many patients do not need pharmacological treatment, as attacks may be infrequent and tolerable. Acute attacks can be ameliorated in some patients with antiemetic drugs such as diphenhydramine, meclizine, and metoclopramide. Frequent attacks may warrant pharmacological prophylaxis with metoprolol, amitriptyline, topiramate, valproic acid, or flunarizine. Nonpharmacological measures including regular exercise, relaxation techniques, stress management, and biofeedback may be similarly effective and can be combined with a pharmacological approach. Limited data indicate that the prognosis appears to be less favorable for vestibular migraine than for migraine headaches.

Keywords

migraine - vertigo - vestibular migraine - treatment - migrainous vertigo - dizziness
 

  • References

  • 1 Beh SC, Masrour S, Smith SV, Friedman DI. The spectrum of vestibular migraine: clinical features, triggers, and examination findings. Headache 2019; 59 (05) 727-740
    CrossrefPubMedGoogle Scholar
  • 2 Britten N, Ukoumunne O. The influence of patients' hopes of receiving a prescription on doctors' perceptions and the decision to prescribe: a questionnaire survey. BMJ 1997; 315 (7121): 1506-1510
    CrossrefPubMedGoogle Scholar
  • 3 Hoffmann TC, Del Mar C. Patients' expectations of the benefits and harms of treatments, screening, and tests: a systematic review. JAMA Intern Med 2015; 175 (02) 274-286
    CrossrefPubMedGoogle Scholar
  • 4 Hoffmann TC, Del Mar C. Clinicians' expectations of the benefits and harms of treatments, screening, and tests: a systematic review. JAMA Intern Med 2017; 177 (03) 407-419
    CrossrefPubMedGoogle Scholar
  • 5 Radtke A, von Brevern M, Neuhauser H, Hottenrott T, Lempert T. Vestibular migraine: long-term follow-up of clinical symptoms and vestibulo-cochlear findings. Neurology 2012; 79 (15) 1607-1614
    CrossrefPubMedGoogle Scholar
  • 6 Soto E, Vega R. Neuropharmacology of vestibular system disorders. Curr Neuropharmacol 2010; 8 (01) 26-40
    CrossrefPubMedGoogle Scholar
  • 7 Flake ZA, Linn BS, Hornecker JR. Practical selection of antiemetics in the ambulatory setting. Am Fam Physician 2015; 91 (05) 293-296
    PubMedGoogle Scholar
  • 8 Kirthi V, Derry S, Moore RA. Aspirin with or without an antiemetic for acute migraine headaches in adults. Cochrane Database Syst Rev 2013; (04) CD008041
    PubMedGoogle Scholar
  • 9 Neuhauser H, Radtke A, von Brevern M, Lempert T. Zolmitriptan for treatment of migrainous vertigo: a pilot randomized placebo-controlled trial. Neurology 2003; 60 (05) 882-883
    CrossrefPubMedGoogle Scholar
  • 10 Prakash S, Shah ND. Migrainous vertigo responsive to intravenous methylprednisolone: case reports. Headache 2009; 49 (08) 1235-1239
    CrossrefPubMedGoogle Scholar
  • 11 Loder E, Burch R, Rizzoli P. The 2012 AHS/AAN guidelines for prevention of episodic migraine: a summary and comparison with other recent clinical practice guidelines. Headache 2012; 52 (06) 930-945
    CrossrefPubMedGoogle Scholar
  • 12 Jackson JL, Kuriyama A, Hayashino Y. Botulinum toxin A for prophylactic treatment of migraine and tension headaches in adults: a meta-analysis. JAMA 2012; 307 (16) 1736-1745
    CrossrefPubMedGoogle Scholar
  • 13 Dodick DW. CGRP ligand and receptor monoclonal antibodies for migraine prevention: evidence review and clinical implications. Cephalalgia 2019; 39 (03) 445-458
    CrossrefPubMedGoogle Scholar
  • 14 Jackson JL, Cogbill E, Santana-Davila R. , et al. A comparative effectiveness meta-analysis of drugs for the prophylaxis of migraine headache. PLoS One 2015; 10 (07) e0130733
    Google Scholar
  • 15 Hepp Z, Bloudek LM, Varon SF. Systematic review of migraine prophylaxis adherence and persistence. J Manag Care Pharm 2014; 20 (01) 22-33
    CrossrefPubMedGoogle Scholar
  • 16 Berger A, Varon SF, Bramley TJ. , et al. Adherence with pharmacological prophylaxis of migraine. Cephalalgia 2009; 29 (Suppl. 01) S56
    PubMedGoogle Scholar
  • 17 Fotuhi M, Glaun B, Quan SY, Sofare T. Vestibular migraine: a critical review of treatment trials. J Neurol 2009; 256 (05) 711-716
    CrossrefPubMedGoogle Scholar
  • 18 Maldonado Fernández M, Birdi JS, Irving GJ, Murdin L, Kivekäs I, Strupp M. Pharmacological agents for the prevention of vestibular migraine. Cochrane Database Syst Rev 2015; 6 (06) CD010600
    CrossrefPubMedGoogle Scholar
  • 19 Bikhazi P, Jackson C, Ruckenstein MJ. Efficacy of antimigrainous therapy in the treatment of migraine-associated dizziness. Am J Otol 1997; 18 (03) 350-354
    PubMedGoogle Scholar
  • 20 Reploeg MD, Goebel JA. Migraine-associated dizziness: patient characteristics and management options. Otol Neurotol 2002; 23 (03) 364-371
    CrossrefPubMedGoogle Scholar
  • 21 Baier B, Winkenwerder E, Dieterich M. “Vestibular migraine”: effects of prophylactic therapy with various drugs. A retrospective study. J Neurol 2009; 256 (03) 436-442
    CrossrefPubMedGoogle Scholar
  • 22 Van Ombergen A, Van Rompaey V, Van de Heyning P, Wuyts F. Vestibular migraine in an otolaryngology clinic: prevalence, associated symptoms, and prophylactic medication effectiveness. Otol Neurotol 2015; 36 (01) 133-138
    CrossrefPubMedGoogle Scholar
  • 23 Lepcha A, Amalanathan S, Augustine AM, Tyagi AK, Balraj A. Flunarizine in the prophylaxis of migrainous vertigo: a randomized controlled trial. Eur Arch Otorhinolaryngol 2014; 271 (11) 2931-2936
    CrossrefPubMedGoogle Scholar
  • 24 Salviz M, Yuce T, Acar H, Karatas A, Acikalin RM. Propranolol and venlafaxine for vestibular migraine prophylaxis: a randomized controlled trial. Laryngoscope 2016; 126 (01) 169-174
    CrossrefPubMedGoogle Scholar
  • 25 Liu F, Ma T, Che X, Wang Q, Yu S. The efficacy of venlafaxine, flunarizine, and valproic acid in the prophylaxis of vestibular migraine. Front Neurol 2017; 8: 524
    CrossrefPubMedGoogle Scholar
  • 26 Power L, Shute W, McOwan B, Murray K, Szmulewicz D. Clinical characteristics and treatment choice in vestibular migraine. J Clin Neurosci 2018; 52: 50-53
    CrossrefPubMedGoogle Scholar
  • 27 Bisdorff AR. Treatment of migraine related vertigo with lamotrigine an observational study. Bull Soc Sci Med Grand Duche Luxemb 2004; 2 (02) 103-108
    PubMedGoogle Scholar
  • 28 Çelebisoy N, Gökçay F, Karahan C. , et al. Acetazolamide in vestibular migraine prophylaxis: a retrospective study. Eur Arch Otorhinolaryngol 2016; 273 (10) 2947-2951
    CrossrefPubMedGoogle Scholar
  • 29 Taghdiri F, Togha M, Razeghi Jahromi S, Refaeian F. Cinnarizine for the prophylaxis of migraine associated vertigo: a retrospective study. Springerplus 2014; 3: 231
    CrossrefPubMedGoogle Scholar
  • 30 Teggi R, Colombo B, Gatti O, Comi G, Bussi M. Fixed combination of cinnarizine and dimenhydrinate in the prophylactic therapy of vestibular migraine: an observational study. Neurol Sci 2015; 36 (10) 1869-1873
    CrossrefPubMedGoogle Scholar
  • 31 Speciali JG, Peres M, Bigal ME. Migraine treatment and placebo effect. Expert Rev Neurother 2010; 10 (03) 413-419
    CrossrefPubMedGoogle Scholar
  • 32 Silberstein SD, Holland S, Freitag F, Dodick DW, Argoff C, Ashman E. ; Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society. Evidence-based guideline update: pharmacologic treatment for episodic migraine prevention in adults: report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society. Neurology 2012; 78 (17) 1337-1345
    CrossrefPubMedGoogle Scholar
  • 33 Wells RE, Bertisch SM, Buettner C, Phillips RS, McCarthy EP. Complementary and alternative medicine use among adults with migraines/severe headaches. Headache 2011; 51 (07) 1087-1097
    CrossrefPubMedGoogle Scholar
  • 34 Penzien DB, Irby MB, Smitherman TA, Rains JC, Houle TT. Well-established and empirically supported behavioral treatment for migraine. Curr Pain Headache Rep 2015; 19 (07) 34
    CrossrefPubMedGoogle Scholar
  • 35 Holroyd KA, Cottrell CK, O'Donnell FJ. , et al. Effect of preventive (beta blocker) treatment, behavioural migraine management, or their combination on outcomes of optimised acute treatment in frequent migraine: randomised controlled trial. BMJ 2010; 341: c4871
    CrossrefPubMedGoogle Scholar
  • 36 Lahmann C, Henningsen P, Brandt T. , et al. Psychiatric comorbidity and psychosocial impairment among patients with vertigo and dizziness. J Neurol Neurosurg Psychiatry 2015; 86 (03) 302-308
    CrossrefPubMedGoogle Scholar
  • 37 Baillie LE, Gabriele JM, Penzien DB. A systematic review of behavioral headache interventions with an aerobic exercise component. Headache 2014; 54 (01) 40-53
    CrossrefPubMedGoogle Scholar
  • 38 Linde K, Allais G, Brinkhaus B. , et al. Acupuncture for the prevention of episodic migraine. Cochrane Database Syst Rev 2016; (06) CD001218
    PubMedGoogle Scholar
  • 39 Rajapakse T, Pringsheim T. Nutraceuticals in migraine: a summary of existing guidelines for use. Headache 2016; 56 (04) 808-816
    CrossrefPubMedGoogle Scholar
  • 40 Lee YY, Yang YP, Huang PI. , et al. Exercise suppresses COX-2 pro-inflammatory pathway in vestibular migraine. Brain Res Bull 2015; 116: 98-105
    CrossrefPubMedGoogle Scholar
  • 41 Alghadir AH, Anwer S. Effects of vestibular rehabilitation in the management of a vestibular migraine: a review. Front Neurol 2018; 9: 440
    CrossrefPubMedGoogle Scholar
  • 42 Neugebauer H, Adrion C, Glaser M, Strupp M. Long-term changes of central ocular motor signs in patients with vestibular migraine. Eur Neurol 2013; 69 (02) 102-107
    CrossrefPubMedGoogle Scholar
  • 43 Kutay Ö, Akdal G, Keskinoğlu P, Balcı BD, Alkın T. Vestibular migraine patients are more anxious than migraine patients without vestibular symptoms. J Neurol 2017; 264 (Suppl. 01) 37-41
    CrossrefPubMedGoogle Scholar
  • 44 Wester JL, Ishiyama A, Ishiyama G. Recurrent vestibular migraine vertigo attacks associated with the development of profound bilateral vestibulopathy: a case series. Otol Neurotol 2017; 38 (08) 1145-1148
    CrossrefPubMedGoogle Scholar